Abstract
Background and aim. Registration trials showed entecavir (ETV) to be a safe and effective therapy for NUC-naïve patients with chronic hepatitis B, but its long-term effectiveness in field practice patients is unknown.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
